Skip to content
2000
image of Redefining Neuropsychiatric Disorder Treatment: Innovations in Drug Design and Targeted Therapy

Abstract

As a major global health problem, neuropsychiatric disorders, including depression, schizophrenia, and bipolar disease, have complex etiologies as well as heterogeneous diagnoses of patient treatment responsiveness. Conventional pharmacotherapy is increasingly the go-to treatment due to its wide utilization, but struggles with a number of symptoms surrounding pain that it can only partially treat because of restrictions in drug phenotype-penetrance and delivery methodologies. All too often, conventional treatments exhibit poor efficacy and side effect profiles, leaving most chronic low back sufferers inadequately treated. Here, we summarize recent breakthroughs on the horizon that could revolutionize the treatment of neuropsychiatric diseases in a review article. We examine the state-of-the-art in drug design and emerging technologies, such as computers and artificial intelligence, which provide tools to pinpoint a specific subset for precision therapy. The review also discusses drug delivery systems, including novel nanoparticle carriers and brain-targeted delivery methods, to enhance the bioavailability and reduce the side effects of the drugs. The authors also discuss the applications of new technologies, such as CRISPR gene editing, for directly correcting disease-causing genes. The purpose of this review is to summarize and synthesize these advances, thereby providing an expansive perspective on neuropsychiatric disorder management in the current context, with pointers towards possible new therapeutic strategies leading to a more precise, patient-targeted treatment approach.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/ddl/10.2174/0122103031375761250801075431
2025-08-07
2025-09-23

  • From This Site

    /content/journals/ddl/10.2174/0122103031375761250801075431
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. Muench J. Hamer A.M. Adverse effects of antipsychotic medications. Am. Fam. Physician 2010 81 5 617 622 20187598
    [Google Scholar]
  2. Maher R. Moreno-Borrallo A. Jindal D. Mai B.T. Ruiz-Hernandez E. Harkin A. Intranasal polymeric and lipid-based nanocarriers for CNS drug delivery. Pharmaceutics 2023 15 3 746 10.3390/pharmaceutics15030746 36986607
    [Google Scholar]
  3. Cook R.O. Pannu R.K. Kellaway I.W. Novel sustained release microspheres for pulmonary drug delivery. J. Control. Release 2005 104 1 79 90 10.1016/j.jconrel.2005.01.003 15866336
    [Google Scholar]
  4. Fein K.C. Arral M.L. Kim J.S. Newby A.N. Whitehead K.A. Placental drug transport and fetal exposure during pregnancy is determined by drug molecular size, chemistry, and conformation. J. Control. Release 2023 361 29 39 10.1016/j.jconrel.2023.07.029 37473809
    [Google Scholar]
  5. Li Q. Shao X. Dai X. Guo Q. Yuan B. Liu Y. Jiang W. Recent trends in the development of hydrogel therapeutics for the treatment of central nervous system disorders. NPG Asia Mater. 2022 14 1 14 10.1038/s41427‑022‑00362‑y
    [Google Scholar]
  6. Karambizi N.U. McMahan C.S. Blue C.N. Temesvari L.A. Global estimated Disability-Adjusted Life-Years (DALYs) of diarrheal diseases: A systematic analysis of data from 28 years of the global burden of disease study. PLoS One 2021 16 10 0259077 10.1371/journal.pone.0259077 34705878
    [Google Scholar]
  7. Nestler E.J. Hyman S.E. Animal models of neuropsychiatric disorders. Nat. Neurosci. 2010 13 10 1161 1169 10.1038/nn.2647 20877280
    [Google Scholar]
  8. Rush A.J. Trivedi M.H. Wisniewski S.R. Nierenberg A.A. Stewart J.W. Warden D. Niederehe G. Thase M.E. Lavori P.W. Lebowitz B.D. McGrath P.J. Rosenbaum J.F. Sackeim H.A. Kupfer D.J. Luther J. Fava M. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: A STAR*D report. Am. J. Psychiatry 2006 163 11 1905 1917 10.1176/ajp.2006.163.11.1905 17074942
    [Google Scholar]
  9. Cipriani A. Furukawa T.A. Salanti G. Chaimani A. Atkinson L.Z. Ogawa Y. Leucht S. Ruhe H.G. Turner E.H. Higgins J.P.T. Egger M. Takeshima N. Hayasaka Y. Imai H. Shinohara K. Tajika A. Ioannidis J.P.A. Geddes J.R. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: A systematic review and network meta-analysis. Lancet 2018 391 10128 1357 1366 10.1016/S0140‑6736(17)32802‑7 29477251
    [Google Scholar]
  10. Correll C.U. Solmi M. Veronese N. Bortolato B. Rosson S. Santonastaso P. Thapa-Chhetri N. Fornaro M. Gallicchio D. Collantoni E. Pigato G. Favaro A. Monaco F. Kohler C. Vancampfort D. Ward P.B. Gaughran F. Carvalho A.F. Stubbs B. Prevalence, incidence and mortality from cardiovascular disease in patients with pooled and specific severe mental illness: A large-scale meta-analysis of 3,211,768 patients and 113,383,368 controls. World Psychiatry 2017 16 2 163 180 10.1002/wps.20420 28498599
    [Google Scholar]
  11. Newcomer J.W. Second-generation (atypical) antipsychotics and metabolic effects: A comprehensive literature review. CNS Drugs 2005 19 1 1 93 10.2165/00023210‑200519001‑00001 15998156
    [Google Scholar]
  12. Pardridge W.M. The blood-brain barrier: Bottleneck in brain drug development. NeuroRx 2005 2 1 3 14 10.1602/neurorx.2.1.3 15717053
    [Google Scholar]
  13. Schork N.J. Personalized medicine: Time for one-person trials. Nature 2015 520 7549 609 611 10.1038/520609a 25925459
    [Google Scholar]
  14. Stoltenberg S.F. Burmeister M. Recent progress in psychiatric genetics-some hope but no hype. Hum. Mol. Genet. 2000 9 6 927 935 10.1093/hmg/9.6.927 10767316
    [Google Scholar]
  15. Elkamhawy A. Lu Q. Nada H. Woo J. Quan G. Lee K. The journey of DDR1 and DDR2 kinase inhibitors as rising stars in the fight against cancer. Int. J. Mol. Sci. 2021 22 12 6535 10.3390/ijms22126535 34207360
    [Google Scholar]
  16. Saraiva C. Praça C. Ferreira R. Santos T. Ferreira L. Bernardino L. Nanoparticle-mediated brain drug delivery: Overcoming blood–brain barrier to treat neurodegenerative diseases. J. Control. Release 2016 235 34 47 10.1016/j.jconrel.2016.05.044 27208862
    [Google Scholar]
  17. Patel T. Zhou J. Piepmeier J.M. Saltzman W.M. Polymeric nanoparticles for drug delivery to the central nervous system. Adv. Drug Deliv. Rev. 2012 64 7 701 705 10.1016/j.addr.2011.12.006 22210134
    [Google Scholar]
  18. Nelson C.E. Gersbach C.A. Engineering delivery vehicles for genome editing. Annu. Rev. Chem. Biomol. Eng. 2016 7 1 637 662 10.1146/annurev‑chembioeng‑080615‑034711 27146557
    [Google Scholar]
  19. Wang D. Zhang F. Gao G. CRISPR-based therapeutic genome editing: Strategies and in vivo delivery by AAV vectors. Cell 2020 181 1 136 150 10.1016/j.cell.2020.03.023 32243786
    [Google Scholar]
  20. Insel T.R. Cuthbert B.N. Brain disorders? Precisely. Science 2015 348 6234 499 500 10.1126/science.aab2358 25931539
    [Google Scholar]
  21. Tamminga C.A. Stan A.D. Wagner A.D. The hippocampal formation in schizophrenia. Am. J. Psychiatry 2010 167 10 1178 1193 10.1176/appi.ajp.2010.09081187 20810471
    [Google Scholar]
  22. Tye K.M. Deisseroth K. Optogenetic investigation of neural circuits underlying brain disease in animal models. Nat. Rev. Neurosci. 2012 13 4 251 266 10.1038/nrn3171 22430017
    [Google Scholar]
  23. Wittenberg G.F. Schaechter J.D. The neural basis of functional recovery after stroke. Clin. Neurophysiol. 2009 120 2 219 230
    [Google Scholar]
  24. Voelkl B. Vogt L. Sena E.S. Würbel H. Reproducibility of preclinical animal research improves with heterogeneity of study samples. PLoS Biol. 2018 16 2 2003693 10.1371/journal.pbio.2003693 29470495
    [Google Scholar]
  25. GBD 2019 Mental Disorders Collaborators. Global burden of mental disorders and the COVID-19 pandemic. Lancet 2022 398 10263 1553 1560
    [Google Scholar]
  26. Zhavoronkov A. Ivanenkov Y.A. Aliper A. Veselov M.S. Aladinskiy V.A. Aladinskaya A.V. Terentiev V.A. Polykovskiy D.A. Kuznetsov M.D. Asadulaev A. Volkov Y. Zholus A. Shayakhmetov R.R. Zhebrak A. Minaeva L.I. Zagribelnyy B.A. Lee L.H. Soll R. Madge D. Xing L. Guo T. Aspuru-Guzik A. Deep learning enables rapid identification of potent DDR1 kinase inhibitors. Nat. Biotechnol. 2019 37 9 1038 1040 10.1038/s41587‑019‑0224‑x 31477924
    [Google Scholar]
  27. Reker D. Schneider G. Active-learning strategies in computer-assisted drug discovery. Drug Discov. Today 2015 20 4 458 465 10.1016/j.drudis.2014.12.004 25499665
    [Google Scholar]
  28. Gao K. Nguyen D.D. Tu M. Generative networks for optimizing drug discovery. ACS Cent. Sci. 2020 6 3 395 404
    [Google Scholar]
  29. Drews J. Drug discovery: A historical perspective. Science 2000 287 5460 1960 1964 10.1126/science.287.5460.1960 10720314
    [Google Scholar]
  30. Kobilka B.K. Deupi X. Conformational complexity of G-protein-coupled receptors. Trends Pharmacol. Sci. 2007 28 8 397 406 10.1016/j.tips.2007.06.003 17629961
    [Google Scholar]
  31. Congreve M. Dias J.M. Marshall F.H. Structure-based drug design for G protein-coupled receptors. Prog. Med. Chem. 2014 53 1 63 10.1016/B978‑0‑444‑63380‑4.00001‑9 24418607
    [Google Scholar]
  32. Claxton S. Bennett J.M. Bayly A.R. Cryo-EM in drug discovery: Achievements, limitations and prospects. Mol Biomed. 2022 3 1 36 36437420
    [Google Scholar]
  33. Tang J.C. Sievers S.A. Kobilka B.K. Structure-based drug design for disease-associated GPCRs. Bioorg. Med. Chem. Lett. 2018 28 18 2836 2846
    [Google Scholar]
  34. Jamal S. Scaria V. Computational tools for modeling G-protein coupled receptors. Receptors as Therapeutic Targets. Cham Springer 2018 239 254
    [Google Scholar]
  35. Ramalho T.C. Cunha E.F. de Lima M.C. Computational chemistry in drug design: Foundations and contemporary applications. J. Biomol. Struct. Dyn. 2022 40 4 1587 1606
    [Google Scholar]
  36. Goetz D.H. Choe Y. Hansell E.J. Substrate specificity profiling and identification of new inhibitors of the major neutral endopeptidase from the human hookworm Ancylostomaceylanicum. Chem. Biol. 2007 14 7 737 746
    [Google Scholar]
  37. Ulugol A. Karadag H.C. Ipci Y. Tamer M. Dokmeci I. The effect of WIN 55,212-2, a cannabinoid agonist, on tactile allodynia in diabetic rats. Neurosci. Lett. 2004 371 2-3 167 170 10.1016/j.neulet.2004.08.061 15519750
    [Google Scholar]
  38. Marquez P.V. Saxena S. Making mental health a global priority. Cerebrum 2016 2016 1 5
    [Google Scholar]
  39. Allison M. Is personalized medicine finally arriving? Nat. Biotechnol. 2008 26 5 509 517 10.1038/nbt0508‑509 18464779
    [Google Scholar]
  40. Saeed U. Lang A.E. Masellis M. Neuroimaging advances in Parkinson’s disease and atypical Parkinsonian syndromes. Front. Neurol. 2020 11 572976 10.3389/fneur.2020.572976 33178113
    [Google Scholar]
  41. Wang Y. Zhang Y. Wang W. Zhang Y. Dong X. Liu Y. Diverse physiological roles of kynurenine pathway metabolites: Updated implications for health and disease. Metabolites 2025 15 3 210 10.3390/metabo15030210 40137174
    [Google Scholar]
  42. Ashley E.A. Towards precision medicine. Nat. Rev. Genet. 2016 17 9 507 522 10.1038/nrg.2016.86 27528417
    [Google Scholar]
  43. Lipska B. Weinberger D.R. To model a psychiatric disorder in animals: Schizophrenia as a reality test. Neuropsychopharmacology 2000 23 3 223 239 10.1016/S0893‑133X(00)00137‑8 10942847
    [Google Scholar]
  44. Wen P.Y. Kesari S. Malignant gliomas in adults. N. Engl. J. Med. 2008 359 5 492 507 10.1056/NEJMra0708126 18669428
    [Google Scholar]
  45. Allen W.E. DeNardo L.A. Chen M.Z. Liu C.D. Loh K.M. Fenno L.E. Ramakrishnan C. Deisseroth K. Luo L. Thirst-associated preoptic neurons encode an aversive motivational drive. Science 2017 357 6356 1149 1155 10.1126/science.aan6747 28912243
    [Google Scholar]
  46. Swinney D.C. Anthony J. How were new medicines discovered? Nat. Rev. Drug Discov. 2011 10 7 507 519 10.1038/nrd3480 21701501
    [Google Scholar]
  47. Macarron R. Banks M.N. Bojanic D. Burns D.J. Cirovic D.A. Garyantes T. Green D.V.S. Hertzberg R.P. Janzen W.P. Paslay J.W. Schopfer U. Sittampalam G.S. Impact of high-throughput screening in biomedical research. Nat. Rev. Drug Discov. 2011 10 3 188 195 10.1038/nrd3368 21358738
    [Google Scholar]
  48. Pushpakom S. Iorio F. Eyers P.A. Escott K.J. Hopper S. Wells A. Doig A. Guilliams T. Latimer J. McNamee C. Norris A. Sanseau P. Cavalla D. Pirmohamed M. Drug repurposing: Progress, challenges and recommendations. Nat. Rev. Drug Discov. 2019 18 1 41 58 10.1038/nrd.2018.168 30310233
    [Google Scholar]
  49. Wang T. Sun J. Zhao Q. Investigating cardiotoxicity related with hERG channel blockers using molecular fingerprints and graph attention mechanism. Comput. Biol. Med. 2023 153 106464 10.1016/j.compbiomed.2022.106464 36584603
    [Google Scholar]
  50. Huang Y. Dong D. Zhang W. Wang R. Lin Y.C.D. Zuo H. Huang H.Y. Huang H.D. DrugRepoBank: A comprehensive database and discovery platform for accelerating drug repositioning. Database 2024 2024 baae051 10.1093/database/baae051 38994794
    [Google Scholar]
  51. Gonzalez-Covarrubias V. Martínez-Martínez E. del Bosque-Plata L. The potential of metabolomics in biomedical applications. Metabolites 2022 12 2 194 10.3390/metabo12020194 35208267
    [Google Scholar]
  52. Berlowitz I. García Torres E. Ruiz Macedo J.C. Wolf U. Maake C. Martin-Soelch C. Traditional Indigenous-Amazonian therapy involving ceremonial tobacco drinking as medicine: A transdisciplinary multi-epistemic observational study. Health Educ. Behav. 2024 51 6 796 808 10.1177/10901981231213348 39360499
    [Google Scholar]
  53. Reese-Petersen A.L. Breisnes H.W. Gabor D. Rønnow S.R. Manoel B. Bajaj M. Arenstorff C.S. Aighobahi E. Vestermark R. Karsdal M.A. Biomarker-guided drug development provides value for patients, payers and drug developers: Lessons learned from 25 years in the biomarker industry. Biomarkers 2024 29 4 222 232 10.1080/1354750X.2024.2342016 38606909
    [Google Scholar]
  54. Islam SU Ahmed MB Ahsan H Lee YS Role of biomarkers in personalized medicine. Cancer Biomarkers in Diagnosis and Therapeutics Shehzad A Singapore Springer 2022 10.1007/978‑981‑16‑5759‑7_10
    [Google Scholar]
  55. Chappell K. Colle R. Bouligand J. Trabado S. Fève B. Becquemont L. Corruble E. Verstuyft C. The MAOA rs979605 genetic polymorphism is differentially Associated with Clinical Improvement following antidepressant treatment between male and female depressed patients. Int. J. Mol. Sci. 2022 24 1 497 10.3390/ijms24010497 36613935
    [Google Scholar]
  56. Ibanez A. Zimmer E.R. Time to synergize mental health with brain health. Nature Mental Health 2023 1 7 441 443 10.1038/s44220‑023‑00086‑0 38867916
    [Google Scholar]
  57. Ward K. Citrome L. Tolerability and safety outcomes of first- line oral second-generation antipsychotics in patients with schizophrenia. Expert Opin. Drug Saf. 2024 23 4 399 409 10.1080/14740338.2024.2328812 38467517
    [Google Scholar]
  58. Lungu P.F. Lungu C.M. Ciobica A. Balmus I.M. Vitalaru R. Mavroudis I. Dobrin R. Cimpeanu M. Gurzu I.L. The effect of antipsychotics on cognition in schizophrenia—a current narrative review. Brain Sci. 2024 14 4 359 10.3390/brainsci14040359 38672011
    [Google Scholar]
  59. Schneider L.H. Pawluk E.J. Milosevic I. Shnaider P. Rowa K. Antony M.M. Musielak N. McCabe R.E. The diagnostic assessment research tool in action: A preliminary evaluation of a semistructured diagnostic interview for DSM-5 disorders. Psychol. Assess. 2022 34 1 21 29 10.1037/pas0001059 34383547
    [Google Scholar]
  60. Borsboom D. Haslbeck J.M.B. Robinaugh D.J. Systems-based approaches to mental disorders are the only game in town. World Psychiatry 2022 21 3 420 422 10.1002/wps.21004 36073701
    [Google Scholar]
  61. Liu Y. Wu W. Cai C. Zhang H. Shen H. Han Y. Patient-derived xenograft models in cancer therapy: Technologies and applications. Signal Transduct. Target. Ther. 2023 8 1 160 10.1038/s41392‑023‑01419‑2 37045827
    [Google Scholar]
  62. Pilmeyer J. Huijbers W. Lamerichs R. Jansen J.F.A. Breeuwer M. Zinger S. Functional MRI in major depressive disorder: A review of findings, limitations, and future prospects. J. Neuroimaging 2022 32 4 582 595 10.1111/jon.13011 35598083
    [Google Scholar]
  63. Forsyth J.K. Bearden C.E. Rethinking the first episode of schizophrenia: Identifying convergent mechanisms during development and moving toward prediction. Am. J. Psychiatry 2023 180 11 792 804 10.1176/appi.ajp.20230736 37908094
    [Google Scholar]
  64. Joly Y. Dalpe G. Genetic discrimination still casts a large shadow in 2022. Eur. J. Hum. Genet. 2022 30 12 1320 1322 10.1038/s41431‑022‑01194‑8 36163420
    [Google Scholar]
  65. Martinez S. Stoyanov K. Carcache L. Unraveling the spectrum: Overlap, distinctions, and nuances of ADHD and ASD in children. Front. Psychiatry 2024 15 1387179 10.3389/fpsyt.2024.1387179 39345916
    [Google Scholar]
  66. Mosleh-Shirazi S. Abbasi M. Moaddeli M. Vaez A. Shafiee M. Kasaee S.R. Amani A.M. Hatam S. Nanotechnology advances in the detection and treatment of cancer: An overview. Nanotheranostics 2022 6 4 400 423 10.7150/ntno.74613 36051855
    [Google Scholar]
  67. Seidu T.A. Kutoka P.T. Asante D.O. Farooq M.A. Alolga R.N. Bo W. Functionalization of nanoparticulate drug delivery systems and its influence in cancer therapy. Pharmaceutics 2022 14 5 1113 10.3390/pharmaceutics14051113 35631699
    [Google Scholar]
  68. Tiwari P. Chandy A. Kumar K. Mishra R. Ahirwar D. Neuroleptic drug induced hyperprolactinaemia: Pathophysiology, safety and acceptability. Asian Pac. J. Reprod. 2013 2 1 69 75 10.1016/S2305‑0500(13)60120‑7
    [Google Scholar]
  69. Alajangi H.K. Kaur M. Sharma A. Rana S. Thakur S. Chatterjee M. Singla N. Jaiswal P.K. Singh G. Barnwal R.P. Blood–brain barrier: Emerging trends on transport models and new-age strategies for therapeutics intervention against neurological disorders. Mol. Brain 2022 15 1 49 10.1186/s13041‑022‑00937‑4 35650613
    [Google Scholar]
  70. Zhang S. Gan L. Cao F. Wang H. Gong P. Ma C. Ren L. Lin Y. Lin X. The barrier and interface mechanisms of the brain barrier, and brain drug delivery. Brain Res. Bull. 2022 190 69 83 10.1016/j.brainresbull.2022.09.017 36162603
    [Google Scholar]
  71. Bhunia S. Kolishetti N. Vashist A. Yndart Arias A. Brooks D. Nair M. Drug delivery to the brain: Recent advances and unmet challenges. Pharmaceutics 2023 15 12 2658 10.3390/pharmaceutics15122658 38139999
    [Google Scholar]
  72. Krishna R.H. Chandraprabha M.N. Monika P. Br T. Chaudhary V. Manjunatha C. Biomolecule conjugated inorganic nanoparticles for biomedical applications: A review. Biotechnol. Genet. Eng. Rev. 2024 40 4 3611 3652 10.1080/02648725.2022.2147678 36424727
    [Google Scholar]
  73. Kaur S. Singh D. A sojourn on liposomal delivery system: Recent advances and future prospects. Assay Drug Dev. Technol. 2023 21 2 48 64 10.1089/adt.2022.089 36856471
    [Google Scholar]
  74. Kállai-Szabó N. Farkas D. Lengyel M. Basa B. Fleck C. Antal I. Microparticles and multi-unit systems for advanced drug delivery. Eur. J. Pharm. Sci. 2024 194 106704 10.1016/j.ejps.2024.106704 38228279
    [Google Scholar]
  75. Pinto M. Silva V. Barreiro S. Silva R. Remião F. Borges F. Fernandes C. Brain drug delivery and neurodegenerative diseases: Polymeric PLGA-based nanoparticles as a forefront platform. Ageing Res. Rev. 2022 79 101658 10.1016/j.arr.2022.101658 35660114
    [Google Scholar]
  76. Del Campo-Montoya R. Luquin M.R. Puerta E. Garbayo E. Blanco-Prieto M.J. Hydrogels for brain repair: Application to Parkinson’s disease. Expert Opin. Drug Deliv. 2022 19 11 1521 1537 10.1080/17425247.2022.2136161 36240170
    [Google Scholar]
  77. Rawal S.U. Patel B.M. Patel M.M. New drug delivery systems developed for brain targeting. Drugs 2022 82 7 749 792 10.1007/s40265‑022‑01717‑z 35596879
    [Google Scholar]
  78. Moos T. Thomsen M.S. Burkhart A. Hede E. Laczek B. Targeted transport of biotherapeutics at the blood-brain barrier. Expert Opin. Drug Deliv. 2023 20 12 1823 1838 10.1080/17425247.2023.2292697 38059358
    [Google Scholar]
  79. Liu J. Wang T. Dong J. Lu Y. The blood–brain barriers: Novel nanocarriers for central nervous system diseases. J. Nanobiotechnology 2025 23 1 146 10.1186/s12951‑025‑03247‑8 40011926
    [Google Scholar]
  80. Duan M. Cao R. Yang Y. Chen X. Liu L. Ren B. Wang L. Goh B.C. Blood–brain barrier conquest in glioblastoma nanomedicine: Strategies, clinical advances, and emerging challenges. Cancers 2024 16 19 3300 10.3390/cancers16193300 39409919
    [Google Scholar]
  81. Wang Y. Sun C. Liu Z. Zhang S. Gao K. Yi F. Zhou W. Liu H. Nanoengineered endocytic biomaterials for stem cell therapy. Adv. Funct. Mater. 2024 34 52 2410714 10.1002/adfm.202410714
    [Google Scholar]
  82. Teleanu R.I. Preda M.D. Niculescu A.G. Vladâcenco O. Radu C.I. Grumezescu A.M. Teleanu D.M. Current strategies to enhance delivery of drugs across the blood–brain barrier. Pharmaceutics 2022 14 5 987 10.3390/pharmaceutics14050987 35631573
    [Google Scholar]
  83. Ajith S. Almomani F. Elhissi A. Husseini G.A. Nanoparticle-based materials in anticancer drug delivery: Current and future prospects. Heliyon 2023 9 11 21227 10.1016/j.heliyon.2023.e21227 37954330
    [Google Scholar]
  84. Zhuo Y. Luo Z. Zhu Z. Wang J. Li X. Zhang Z. Guo C. Wang B. Nie D. Gan Y. Hu G. Yu M. Direct cytosolic delivery of siRNA via cell membrane fusion using cholesterol-enriched exosomes. Nat. Nanotechnol. 2024 19 12 1858 1868 10.1038/s41565‑024‑01785‑0 39300226
    [Google Scholar]
  85. Song Y. Hu C. Fu Y. Gao H. Modulating the blood–brain tumor barrier for improving drug delivery efficiency and efficacy. VIEW 2022 3 1 20200129 10.1002/VIW.20200129
    [Google Scholar]
  86. Lu Q. Yu H. Zhao T. Zhu G. Li X. Nanoparticles with transformable physicochemical properties for overcoming biological barriers. Nanoscale 2023 15 32 13202 13223 10.1039/D3NR01332D 37526946
    [Google Scholar]
  87. Neri S. Gasparini S. Pascarella A. Santangelo D. Cianci V. Mammì A. Lo Giudice M. Ferlazzo E. Aguglia U. Epilepsy in cerebrovascular diseases: A narrative review. Curr. Neuropharmacol. 2023 21 8 1634 1645 10.2174/1570159X20666220706113925 35794769
    [Google Scholar]
  88. Ndemazie N.B. Inkoom A. Morfaw E.F. Smith T. Aghimien M. Ebesoh D. Agyare E. Multi-disciplinary approach for drug and gene delivery systems to the brain. AAPS PharmSciTech 2022 23 1 11 10.1208/s12249‑021‑02144‑1 34862567
    [Google Scholar]
  89. Wu J.R. Hernandez Y. Miyasaki K.F. Kwon E.J. Engineered nanomaterials that exploit blood-brain barrier dysfunction for delivery to the brain. Adv. Drug Deliv. Rev. 2023 197 114820 10.1016/j.addr.2023.114820 37054953
    [Google Scholar]
  90. Gupta R. Ghosh A. Chakravarti R. Singh R. Ravichandiran V. Swarnakar S. Ghosh D. Cas13d: A new molecular scissor for transcriptome engineering. Front. Cell Dev. Biol. 2022 10 866800 10.3389/fcell.2022.866800 35433685
    [Google Scholar]
  91. Mattar C.N.Z. Chew W.L. Lai P.S. Embryo and fetal gene editing: Technical challenges and progress toward clinical applications. Mol. Ther. Methods Clin. Dev. 2024 32 2 101229 10.1016/j.omtm.2024.101229 38533521
    [Google Scholar]
  92. Asmamaw Mengstie M. Teshome Azezew M. Asmamaw Dejenie T. Teshome A.A. Tadele Admasu F. Behaile Teklemariam A. Tilahun Mulu A. Mekonnen Agidew M. Adugna D.G. Geremew H. Abebe E.C. Recent advancements in reducing the off-target effect of CRISPR-Cas9 genome editing. Biologics 2024 18 21 28 38260716
    [Google Scholar]
  93. Datta A. Sarmah D. Kaur H. Chaudhary A. Vadak N. Borah A. Shah S. Wang X. Bhattacharya P. Advancement in CRISPR/Cas9 technology to better understand and treat neurological disorders. Cell. Mol. Neurobiol. 2023 43 3 1019 1035 10.1007/s10571‑022‑01242‑3 35751791
    [Google Scholar]
  94. Kurishev A.O. Karpov D.S. Nadolinskaia N.I. Goncharenko A.V. Golimbet V.E. CRISPR/Cas-based approaches to study schizophrenia and other neurodevelopmental disorders. Int. J. Mol. Sci. 2022 24 1 241 10.3390/ijms24010241 36613684
    [Google Scholar]
  95. Xiao L. Hareendran S. Loh Y.P. Function of exosomes in neurological disorders and brain tumors. Extrac. Vesic. Circul. Nucl. Acids 2021 2 1 55 79 10.20517/evcna.2021.04 34368812
    [Google Scholar]
  96. Conklin B. Conley B.M. Hou Y. Chen M. Lee K.B. Advanced theragnostics for the central nervous system (CNS) and neurological disorders using functional inorganic nanomaterials. Adv. Drug Deliv. Rev. 2023 192 114636 10.1016/j.addr.2022.114636 36481291
    [Google Scholar]
  97. Proietti T. Bandini A. Wearable technologies for monitoring upper extremity functions during daily life in neurologically impaired individuals. Front. Neurol. 2023 14 1234
    [Google Scholar]
  98. Boeken T. Deep learning frameworks for MRI-based diagnosis of neurological disorders: A systematic review and meta-analysis. Artif. Intell. Rev. 2025 58 1 171 203
    [Google Scholar]
  99. Zheng F. Wang L. Zeng Z. Wu S. International technologies on prevention and treatment of neurological and psychiatric diseases: Bibliometric analysis of patents. JMIR Ment. Health 2022 9 2 25238 10.2196/25238 35191849
    [Google Scholar]
  100. Tiwari P. Panik R. Bhattacharya A. Ahirwar D. Chandy A. Evidences of possible side effects of neuroleptic drugs: A systematic review. Asian Pac. J. Reprod. 2012 1 4 330 336 10.1016/S2305‑0500(13)60105‑0
    [Google Scholar]
  101. Uyanik H. Sengur A. Salvi M. Tan R.S. Tan J.H. Acharya U.R. Automated detection of neurological and mental health disorders using EEG signals and artificial intelligence: A systematic review. Wiley Interdiscip. Rev. Data Min. Knowl. Discov. 2025 15 1 70002 10.1002/widm.70002
    [Google Scholar]
  102. Tanaka M. Battaglia S. Giménez-Llort L. Chen C. Hepsomali P. Avenanti A. Vécsei L. Innovation at the intersection: Emerging translational research in neurology and psychiatry. Cells 2024 13 10 790 10.3390/cells13100790 38786014
    [Google Scholar]
  103. Andreassen O.A. Hindley G.F.L. Frei O. Smeland O.B. New insights from the last decade of research in psychiatric genetics: Discoveries, challenges and clinical implications. World Psychiatry 2023 22 1 4 24 10.1002/wps.21034 36640404
    [Google Scholar]
  104. Nami M. Thatcher R. Kashou N. Lopes D. Lobo M. Bolanos J.F. Morris K. Sadri M. Bustos T. Sanchez G.E. Mohd-Yusof A. Fiallos J. Dye J. Guo X. Peatfield N. Asiryan M. Mayuku-Dore A. Krakauskaite S. Soler E.P. Cramer S.C. Besio W.G. Berenyi A. Tripathi M. Hagedorn D. Ingemanson M. Gombosev M. Liker M. Salimpour Y. Mortazavi M. Braverman E. Prichep L.S. Chopra D. Eliashiv D.S. Hariri R. Tiwari A. Green K. Cormier J. Hussain N. Tarhan N. Sipple D. Roy M. Yu J.S. Filler A. Chen M. Wheeler C. Ashford J.W. Blum K. Zelinsky D. Yamamoto V. Kateb B. A proposed brain-, spine-, and mental-health screening methodology (NEUROSCREEN) for healthcare systems: Position of the society for brain mapping and therapeutics. J. Alzheimers Dis. 2022 86 1 21 42 10.3233/JAD‑215240 35034899
    [Google Scholar]
  105. Lohaus T. Rogalla S. Thoma P. Use of technologies in the therapy of social cognition deficits in neurological and mental diseases: A systematic review. Telemed. J. E Health 2023 29 3 331 351 10.1089/tmj.2022.0037 35532968
    [Google Scholar]
  106. Taslim S. Shadmani S. Saleem A.R. Kumar A. Brahma F.N.U. Blank N. Bashir M.A. Ansari D. Kumari K. Tanveer M. Varrassi G. Kumar S. Raj A. Neuropsychiatric disorders: Bridging the gap between Neurology and Psychiatry. Cureus 2024 16 1 51655 10.7759/cureus.51655 38313968
    [Google Scholar]
  107. Wang Q. Yang F. Quan L. Fu M. Yang Z. Wang J. Knowledge graph and its application in the study of neurological and mental disorders. Front. Psychiatry 2025 16 1452557 10.3389/fpsyt.2025.1452557 40171303
    [Google Scholar]
  108. Jahn F.S. Skovbye M. Obenhausen K. Jespersen A.E. Miskowiak K.W. Cognitive training with fully immersive virtual reality in patients with neurological and psychiatric disorders: A systematic review of randomized controlled trials. Psychiatry Res. 2021 300 113928 10.1016/j.psychres.2021.113928 33857847
    [Google Scholar]
  109. Ma D. Zhang H. Wang L. Editorial: Deep learning methods and applications in brain imaging for the diagnosis of neurological and psychiatric disorders. Front. Neurosci. 2024 18 1497417 10.3389/fnins.2024.1497417 39411146
    [Google Scholar]
  110. Hampsey E. Meszaros M. Skirrow C. Strawbridge R. Taylor R.H. Chok L. Aarsland D. Al-Chalabi A. Chaudhuri R. Weston J. Fristed E. Podlewska A. Awogbemila O. Young A.H. Protocol for Rhapsody: A longitudinal observational study examining the feasibility of speech phenotyping for remote assessment of neurodegenerative and psychiatric disorders. BMJ Open 2022 12 6 061193 10.1136/bmjopen‑2022‑061193 35667724
    [Google Scholar]
  111. Luo L. You W. DelBello M.P. Gong Q. Li F. Recent advances in psychoradiology. Phys. Med. Biol. 2022 67 23 23TR01 10.1088/1361‑6560/ac9d1e 36279868
    [Google Scholar]
  112. Kansal R. The CRISPR-Cas system and clinical applications of CRISPR-based gene editing in hematology with a focus on inherited germline predisposition to hematologic malignancies. Genes 2024 15 7 863 10.3390/genes15070863 39062641
    [Google Scholar]
  113. Giammalva G.R. Gagliardo C. Marrone S. Paolini F. Gerardi R.M. Umana G.E. Yağmurlu K. Chaurasia B. Scalia G. Midiri F. La Grutta L. Basile L. Gulì C. Messina D. Pino M.A. Graziano F. Tumbiolo S. Iacopino D.G. Maugeri R. Focused ultrasound in neuroscience. State of the art and future perspectives. Brain Sci. 2021 11 1 84 10.3390/brainsci11010084 33435152
    [Google Scholar]
  114. Muetunda F. Sabry S. Jamil M.L. Pais S. Dias G. Cordeiro J. AI-assisted diagnosing, monitoring and treatment of mental disorders: A survey. ACM Trans. Comp. Healthcare 2024 5 4 1 24 10.1145/3681794
    [Google Scholar]
  115. Krainc D. Martin W.J. Casey B. Jensen F.E. Tishkoff S. Potter W.Z. Hyman S.E. Shifting the trajectory of therapeutic development for neurological and psychiatric disorders. Sci. Transl. Med. 2023 15 720 eadg4775 10.1126/scitranslmed.adg4775 38190501
    [Google Scholar]
  116. Zhang J. Yu T. Wang M. Zhang Y. Li H. Chen H. Qian Y. Yan L. Clinical applications of functional near-infrared spectroscopy in the past decade: A bibliometric study. Appl. Spectrosc. Rev. 2024 59 7 908 934 10.1080/05704928.2023.2268416
    [Google Scholar]
  117. Benster L.L. Weissman C.R. Stolz L.A. Daskalakis Z.J. Appelbaum L.G. Pre-clinical indications of brain stimulation treatments for non-affective psychiatric disorders, a status update. Transl. Psychiatry 2023 13 1 390 10.1038/s41398‑023‑02673‑2 38097566
    [Google Scholar]
  118. Henn M.C. Smith H.D. Lopez Ramos C.G. Shafie B. Abaricia J. Stevens I. Rockhill A.P. Cleary D.R. Raslan A.M. A systematic review of focused ultrasound for psychiatric disorders: Current applications, opportunities, and challenges. Neurosurg. Focus 2024 57 3 E8 10.3171/2024.6.FOCUS24278 39217636
    [Google Scholar]
  119. Blom D.J. Marais A.D. Moodley R. van der Merwe N. van Tonder A. Raal F.J. RNA-based therapy in the management of lipid disorders: A review. Lipids Health Dis. 2022 21 1 41 10.1186/s12944‑022‑01649‑3 35459248
    [Google Scholar]
  120. Wang H. Meng Q. Qian J. Li M. Gu C. Yang Y. Review: RNA-based diagnostic markers discovery and therapeutic targets development in cancer. Pharmacol. Ther. 2022 234 108123 10.1016/j.pharmthera.2022.108123 35121000
    [Google Scholar]
  121. Esquerda M. Palau F. Lorenzo D. Cambra F.J. Bofarull M. Cusi V. Interdisciplinar en Bioetica G. Ethical questions concerning newborn genetic screening. Clin. Genet. 2021 99 1 93 98 10.1111/cge.13828 32779199
    [Google Scholar]
  122. Ranisch R. Trettenbach K. Arnason G. Initial heritable genome editing: Mapping a responsible pathway from basic research to the clinic. Med. Health Care Philos. 2023 26 1 21 35 10.1007/s11019‑022‑10115‑x 36414813
    [Google Scholar]
  123. Hickey B.A. Chalmers T. Newton P. Lin C.T. Sibbritt D. McLachlan C.S. Clifton-Bligh R. Morley J. Lal S. Smart devices and wearable technologies to detect and monitor mental health conditions and stress: A systematic review. Sensors 2021 21 10 3461 10.3390/s21103461 34065620
    [Google Scholar]
  124. Habr D. Singh M. Uehara R. Diversity in oncology clinical trials: Current landscape for industry-sponsored clinical trials in Asia. Oncol. Ther. 2024 12 1 115 129 10.1007/s40487‑023‑00254‑3 38064162
    [Google Scholar]
  125. Launders N. Kirsh L. Osborn D.P.J. Hayes J.F. The temporal relationship between severe mental illness diagnosis and chronic physical comorbidity: A UK primary care cohort study of disease burden over 10 years. Lancet Psychiatry 2022 9 9 725 735 10.1016/S2215‑0366(22)00225‑5 35871794
    [Google Scholar]
  126. Verma A.K. Mandal S. Tiwari A. Monachesi C. Catassi G.N. Srivastava A. Gatti S. Lionetti E. Catassi C. Current status and perspectives on the application of CRISPR/Cas9 gene-editing system to develop a low-gluten, non-transgenic wheat variety. Foods 2021 10 10 2351 10.3390/foods10102351 34681400
    [Google Scholar]
  127. Taquet M. Sillett R. Zhu L. Mendel J. Camplisson I. Dercon Q. Harrison P.J. Neurological and psychiatric risk trajectories after SARS-CoV-2 infection: An analysis of 2-year retrospective cohort studies including 1 284 437 patients. Lancet Psychiatry 2022 9 10 815 827 10.1016/S2215‑0366(22)00260‑7 35987197
    [Google Scholar]
  128. Cerasa A. Gaggioli A. Marino F. Riva G. Pioggia G. The promise of the metaverse in mental health: The new era of MEDverse. Heliyon 2022 8 11 11762 10.1016/j.heliyon.2022.e11762 36458297
    [Google Scholar]
  129. Leigh S Turner M Pillai GC Considerations and regulatory affairs for clinical research in special populations. Basics and Clinical Applications of Drug Disposition in Special Populations New York, NY, USA John Wiley & Sons Inc. 2025 377 433
    [Google Scholar]
  130. Mendell J.R. Al-Zaidy S.A. Rodino-Klapac L.R. Goodspeed K. Gray S.J. Kay C.N. Boye S.L. Boye S.E. George L.A. Salabarria S. Corti M. Byrne B.J. Tremblay J.P. Current clinical applications of in vivo gene therapy with AAVs. Mol. Ther. 2021 29 2 464 488 10.1016/j.ymthe.2020.12.007 33309881
    [Google Scholar]
  131. Guo R. Guo H. Wang L. Chen M. Yang D. Li B. Development and application of emotion recognition technology — a systematic literature review. BMC Psychol. 2024 12 1 95 10.1186/s40359‑024‑01581‑4 38402398
    [Google Scholar]
  132. Xu Y. Song X. Wang D. Wang Y. Li P. Li J. Proteomic insights into synaptic signaling in the brain: The past, present and future. Mol. Brain 2021 14 1 37 10.1186/s13041‑021‑00750‑5 33596935
    [Google Scholar]
  133. Zhou J. Fangma Y. Chen Z. Zheng Y. Post-stroke neuropsychiatric complications: Types, pathogenesis, and therapeutic intervention. Aging Dis. 2023 14 6 2127 2152 10.14336/AD.2023.0310‑2 37199575
    [Google Scholar]
  134. Behl T. Kaur G. Sehgal A. Singh S. Bhatia S. Al-Harrasi A. Zengin G. Bungau S.G. Munteanu M.A. Brisc M.C. Andronie-Cioara F.L. Brisc C. Elucidating the multi-targeted role of nutraceuticals: A complementary therapy to starve neurodegenerative diseases. Int. J. Mol. Sci. 2021 22 8 4045 10.3390/ijms22084045 33919895
    [Google Scholar]
  135. Morris G. Schorge S. Gene therapy for neurological disease: State of the art and opportunities for next-generation approaches. Neuroscience 2022 490 309 314 10.1016/j.neuroscience.2022.03.010 35304290
    [Google Scholar]
  136. Westwood S.J. Conti A.A. Tang W. Xue S. Cortese S. Rubia K. Clinical and cognitive effects of external trigeminal nerve stimulation (eTNS) in neurological and psychiatric disorders: A systematic review and meta-analysis. Mol. Psychiatry 2023 28 10 4025 4043 10.1038/s41380‑023‑02227‑4 37674019
    [Google Scholar]
  137. Kaur P. Rajput A. Singh D. Singh G. Mehra A. Kaur S. Bedi N. Arora S. The sojourn of polymeric micelles for effective brain drug delivery system. Curr. Drug Deliv. 2024 21 1 65 79 10.2174/1567201820666230413082352 37069713
    [Google Scholar]
  138. Edsjö A. Holmquist L. Geoerger B. Nowak F. Gomon G. Alix-Panabières C. Staaf J. Ploeger C. Lassen U. Le Tourneau C. Lehtiö J. Ott P.A. von Deimling A. Fröhling S. Voest E. Klauschen F. Dienstmann R. Alshibany A. Siu L.L. Stenzinger A. Precision cancer medicine: Concepts, current practice, and future developments. J. Intern. Med. 2023 294 4 455 481 10.1111/joim.13709 37641393
    [Google Scholar]
  139. Manchia M. Pisanu C. Squassina A. Carpiniello B. Challenges and future prospects of precision medicine in psychiatry. Pharm. Genomics Pers. Med. 2020 13 127 140 10.2147/PGPM.S198225 32425581
    [Google Scholar]
  140. Chapman J. Hsu T. Chen X. Heo T.W. Wood B.C. Quantifying disorder one atom at a time using an interpretable graph neural network paradigm. Nat. Commun. 2023 14 1 4030 10.1038/s41467‑023‑39755‑0 37419927
    [Google Scholar]
  141. Miller J.B. Big data and biomedical informatics: Preparing for the modernization of clinical neuropsychology. Clin. Neuropsychol. 2019 33 2 287 304 10.1080/13854046.2018.1523466 30513257
    [Google Scholar]
  142. Ilomäki J. Bell J.S. Chan A.Y.L. Tolppanen A.M. Luo H. Wei L. Lai E.C.C. Shin J.Y. De Paoli G. Pajouheshnia R. Ho F.K. Reynolds L. Lau K.K. Crystal S. Lau W.C.Y. Man K.K.C. Brauer R. Chan E.W. Shen C.Y. Kim J.H. Lum T.Y.S. Hartikainen S. Koponen M. Rooke E. Bazelier M. Klungel O. Setoguchi S. Pell J.P. Cook S. Wong I.C.K. Application of healthcare ‘Big Data’in CNS drug research: The example of the neurological and mental health Global Epidemiology Network (NeuroGEN). CNS Drugs 2020 34 9 897 913 10.1007/s40263‑020‑00742‑4 32572794
    [Google Scholar]
  143. Scangos K.W. State M.W. Miller A.H. Baker J.T. Williams L.M. New and emerging approaches to treat psychiatric disorders. Nat. Med. 2023 29 2 317 333 10.1038/s41591‑022‑02197‑0 36797480
    [Google Scholar]
  144. Frank P. Batty G.D. Pentti J. Jokela M. Poole L. Ervasti J. Vahtera J. Lewis G. Steptoe A. Kivimäki M. Association between depression and physical conditions requiring hospitalization. JAMA Psychiatry 2023 80 7 690 699 10.1001/jamapsychiatry.2023.0777 37133850
    [Google Scholar]
  145. Paraschiv E.A. Băjenaru L. Petrache C. Bica O. Nicolau D.N. AI-driven neuro-monitoring: Advancing schizophrenia detection and management through deep learning and EEG analysis. Future Internet 2024 16 11 424 10.3390/fi16110424
    [Google Scholar]
  146. Hempel S. Bolshakova M. Hochman M. Jimenez E. Thompson G. Motala A. Ganz D.A. Gabrielian S. Edwards S. Zenner J. Dennis B. Chang E. Caring for high-need patients. BMC Health Serv. Res. 2023 23 1 1289 10.1186/s12913‑023‑10236‑w 37996845
    [Google Scholar]
  147. Khodosevich K. Dragicevic K. Howes O. Drug targeting in psychiatric disorders — how to overcome the loss in translation? Nat. Rev. Drug Discov. 2024 23 3 218 231 10.1038/s41573‑023‑00847‑7 38114612
    [Google Scholar]
  148. Giacobbe P. Burhan A.M. Waxman R. Ng E. Interventional psychiatry and neurotechnologies: Education and ethics training. Can. J. Neurol. Sci. 2023 50 s1 s10 s16 10.1017/cjn.2023.27 37160678
    [Google Scholar]
  149. Ercoli T. Loy F. Masala C. Solla P. Neurological and psychiatric disorders in the COVID-19 era. Brain Sci. 2024 14 4 355 10.3390/brainsci14040355 38672007
    [Google Scholar]
/content/journals/ddl/10.2174/0122103031375761250801075431
Loading
Redefining Neuropsychiatric Disorder Treatment: Innovations in Drug Design and Targeted Therapy
Bentham Science Publishers ; https://doi.org/10.2174/0122103031375761250801075431
/content/journals/ddl/10.2174/0122103031375761250801075431
/content/journals/ddl/10.2174/0122103031375761250801075431
Loading

Data & Media loading...


  • Article Type:     Review Article
Keywords: brain-targeted therapy ; neuropsychiatric disorders ; Computational drug discovery ; biomarkers ; nanotechnology ; precision medicine

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test